Research programme: protein modulators - PTC Therapeutics

Drug Profile

Research programme: protein modulators - PTC Therapeutics

Alternative Names: DBMD-Utrophin; DMD Exon-51; Project Catalyst; SERCA2a protein stimulants - PTC Therapeutics

Latest Information Update: 28 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Dystrophin expression modulators; Insulin-like growth factor I stimulants; Myostatin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase stimulants; Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Duchenne muscular dystrophy

Most Recent Events

  • 28 Jan 2014 Early research for Duchenne muscular dystrophy is ongoing in USA (PO)
  • 15 Dec 2011 This programme is still in active development
  • 31 Dec 2003 Early research in Duchenne muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top